Jonathan Skinner on Health Care Costs, Technology, and Rising Mortality
What this covers
Jonathan Skinner of Dartmouth College joins Russ Roberts to examine a puzzle: why health care spending rises without commensurate gains in health outcomes, while genuine health crises go unaddressed. The conversation moves from the institutional roots of health care cost inflation—how the FDA and Medicare certify treatments for mere effectiveness rather than cost-effectiveness or comparison to existing alternatives—through the role of spending other people's money in dulling price sensitivity, to a troubling epidemiological reversal: rising mid-life mortality among white Americans, driven largely by opioid-related deaths.
The discussion unfolds across several distinct problems. Skinner traces how randomized trials conducted on ideal patients in ideal settings get misapplied to the marginal patient in ordinary care, how natural monopolies in hospital markets encourage price exploitation over cost reduction, and how imaging technologies like advanced mammography create overdiagnosis by flagging benign abnormalities. He categorizes health technologies into three types—clear life-savers, treatments of uncertain broader benefit, and those without good evidence—and argues resources have flowed toward expensive marginal-benefit treatments while opioid use has metastasized into a public health catastrophe. The conversation also covers geographic variation in medical practice, the physiological mechanisms that lock patients into opioid dependence, and why the DNA revolution has delivered less than expected for medicine. Throughout, Skinner and Roberts grapple with a core tension: physicians trained to help suffering patients face genuine difficulty in restraining cost when a patient demands action, however marginal its benefit.
Skinner argues that health care defies the normal pattern where technology lowers cost and raises quality, because the regulatory and payment system certifies treatments for mere effectiveness (not comparative cost-effectiveness) and insulates patients from prices, so spending rises without commensurate outcome gains; meanwhile real health gains are being missed, as shown by rising mid-life white mortality tied to opioids.
- FDA/Medicare certify treatments against placebo or for effectiveness, not against the next-best alternative, so costly no-better technologies proliferate
- Declining out-of-pocket share dulls price sensitivity, and health care often functions as a natural monopoly with huge price/utilization variation
- Resources flow to expensive marginal-benefit technologies while opioid-related mortality among middle-aged whites rises
When people spend other people's money instead of their own, they purchase less carefully and choose less valuable items, driving rising national health spending.
- Out-of-pocket spending as a share of total health spending has slowly declined in the US over the last 50 years, correlating with rising national health spending; this is not just correlation but causation, because when people spend other people's money they buy things less carefully and are likely to purchase items less valuable than they would if paying out of pocket.
“out-of-pocket spending as a proportion of total spending has slowly declined in the United States over the last 50 years; and that correlates with a nice increase in how much we spend as a nation. And I think there's a relationship there that's not just correlation but causation.”
- If made Health Care Czar, Roberts would dismantle most of the interventions intended to improve health care, let a thousand flowers bloom, and rely on private charity and civil society to care for those who cannot afford treatments that would themselves be cheaper once artificial demand stops pushing prices up.
“I'd just dismantle most of the things that we've tried to mantle to make things better... And I'd let a thousand flowers bloom; and I'd let private charity and civil society take care of people who couldn't afford the health care treatments”
Health care prices vary dramatically across regions unlike other consumer goods, isolating pricing dysfunction as the distinctive market failure in health care.
- Geographic variation in consumption is not unique to health care—chicken or regional food consumption varies just as much across the country—but unlike health care, the prices of those goods do not vary anywhere near as much, isolating price variation as the distinctive feature of health care markets.
“people in Philadelphia are more likely to consume Philadelphia cheese steaks; people in California are going to eat salads... It showed just as much variation across the country in chicken consumption.”
Medical technology prices remain high because manufacturers lack incentive to produce cheaper versions, unlike other industries where consumer cost-consciousness drives marginal-cost decline.
- Prices for medical technology don't fall the way they do in other industries because elsewhere people have an incentive to spend their money carefully, whereas in health care manufacturers simply build a better, more expensive version with no incentive to produce a cheaper one—so the marginal-cost decline seen with electronics like ballpoint pens does not materialize.
“they come down everywhere else because people have an incentive to spend their money carefully. Here, they just make a better one, that's more expensive. There's no incentive to make a cheaper one. That's the problem.”
Individual treatment outcomes lack credibility without randomized trials because counterfactuals are unknown, making anecdotal recovery evidence unreliable for causal inference.
- Individual testimonials about treatments saving a life or therapy helping are unreliable because there is no counterfactual—Roberts's shoulder improved after he stopped physical therapy, illustrating that without knowing what would have happened otherwise, one cannot attribute outcomes to a treatment, which is why randomized trials are valuable.
“if I'd continued, I would have said, 'What a great physical therapist I have!' But now I've learned that the key for shoulder pain is to get physical therapy and then stop... causation is tricky.”